3RUM

New strategy to analyze structures of glycopeptide antibiotic-target complexes

3RUM の概要

• エントリーDOI: 10.2210/pdb3rum/pdb
• 関連するPDBエントリー: 1ANF 3RUL 3RUN 3VFJ 3VFK
• 関連するBIRD辞書のPRD_ID: PRD_900001
• 分子名称: Maltose-binding periplasmic protein, Ristocetin, alpha-D-arabinofuranose-(1-2)-alpha-D-mannopyranose-(1-2)-[alpha-L-rhamnopyranose-(1-6)]beta-D-glucopyranose, ... (9 entities in total)
• 機能のキーワード: antibiotic, glycopeptide, native protein ligation, fusion, carboxymethylation of cysteine, ristocetin, sugar binding protein-antibiotic complex, sugar binding protein/antibiotic
• 由来する生物種: Escherichia coli K-12; 詳細
• 細胞内の位置: Periplasm: P0AEX9
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 46509.67

構造登録者

Economou, N.J.,Weeks, S.D.,Grasty, K.C.,Nahoum, V.,Loll, P.J. (登録日: 2011-05-05, 公開日: 2012-06-06, 最終更新日: 2023-12-06)

主引用文献

Economou, N.J.,Nahoum, V.,Weeks, S.D.,Grasty, K.C.,Zentner, I.J.,Townsend, T.M.,Bhuiya, M.W.,Cocklin, S.,Loll, P.J.
A carrier protein strategy yields the structure of dalbavancin.
J.Am.Chem.Soc., 134:4637-4645, 2012

PubMed Abstract: Many large natural product antibiotics act by specifically binding and sequestering target molecules found on bacterial cells. We have developed a new strategy to expedite the structural analysis of such antibiotic-target complexes, in which we covalently link the target molecules to carrier proteins, and then crystallize the entire carrier-target-antibiotic complex. Using native chemical ligation, we have linked the Lys-D-Ala-D-Ala binding epitope for glycopeptide antibiotics to three different carrier proteins. We show that recognition of this peptide by multiple antibiotics is not compromised by the presence of the carrier protein partner, and use this approach to determine the first-ever crystal structure for the new therapeutic dalbavancin. We also report the first crystal structure of an asymmetric ristocetin antibiotic dimer, as well as the structure of vancomycin bound to a carrier-target fusion. The dalbavancin structure reveals an antibiotic molecule that has closed around its binding partner; it also suggests mechanisms by which the drug can enhance its half-life by binding to serum proteins, and be targeted to bacterial membranes. Notably, the carrier protein approach is not limited to peptide ligands such as Lys-D-Ala-D-Ala, but is applicable to a diverse range of targets. This strategy is likely to yield structural insights that accelerate new therapeutic development.

PubMed: 22352468
DOI: 10.1021/ja208755j

実験手法

X-RAY DIFFRACTION (1.851 Å)